Abstract 57P
Background
Expanded use of tumour molecular testing to enable targeted treatment across multiple cancers has increased identification of potential pathogenic germline variants (pPGVs). In NSCLC, BRCA1 and BRCA2 are two potentially targetable pPGVs that are not well described despite BRCA-mutated lung cancer accounting for 1%-14% of cases. This study evaluates the frequency of BRCA1/2-mutated NSCLC identified via tumour sequencing and describes patient and tumour characteristics, family history, clinical course, and germline BRCA mutational status.
Methods
NSCLC patients who underwent tumour testing between January 1, 2018 and June 30, 2021 were identified. Next generation sequencing was used to screen for 46 tumour gene mutations including BRCA1/2, with subsequent referral for germline testing via gene specific intronic polymerase chain reaction amplification if pPGVs were identified.
Results
Of 2784 patients with NSCLC who had tumour sequencing, 44 (1.6%) had pPGVs in BRCA1/2. The majority of patients had metastatic disease at diagnosis (59.1%) and a family history of cancer in a first-degree relative (56.8%), while 34.1% had personal history of a second primary cancer. Frequently co-mutated genes were TP53 (68.2%), KRAS (40.1%), and EGFR (20.5%). Of patients who had confirmatory testing, 60% (12/20) were confirmed germline BRCA1/2 carriers. Patients with stage IV disease at time of diagnosis with germline BRCA1/2 mutation had shortened overall survival (18.7 ± 4.6 months) when compared to the 8 patients with confirmed somatic BRCA1/2 mutation (63.8 ± 21.8 months, p = 0.027).
Conclusions
BRCA1/2 tumour mutations were detected with frequency consistent with prior reports and exhibit high likelihood of associated germline mutation. The observed difference in survival of patients with advanced disease harbouring somatic versus germline mutation warrants further study and highlights the importance of confirmatory germline testing as targeted therapies emerge in order to adequately prognosticate and inform families of at-risk status.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract